manualshive.com logo in svg

St. Jude Medical CardioMEMS CM1000, User Manual

Share
Download
St. Jude Medical CardioMEMS CM1000 User Manual Download Page 14

Study Endpoints 
 
The primary and secondary endpoints were evaluated after 6 months of patient follow-up.  
The primary safety endpoints were 1) Freedom from device / system-related 
complications (DSRC), and 2) Freedom from pressure sensor failures.  The primary 
efficacy endpoint was the rate of HF hospitalizations.  All hospitalizations were 
adjudicated by an independent Clinical Events Committee (CEC) who were blinded to 
treatment assignment.   Secondary endpoints were tested in a hierarchical fashion and 
included changes in PA pressures, proportion of subjects hospitalized for HF, days alive 
outside of the hospital for HF, and quality of life.  Because blinded follow-up continued 
until the last patient completed 6 months of follow-up, the average patient follow-up was 
much longer (17.6 months) and pre-specified supplementary analyses were conducted on 
the full duration of follow-up data (Randomized Access). 

 

Patient Demographics and Disposition  

575 patients were consented for trial enrollment and underwent right heart catheterization. 
Of these 575 patients, 25 (4.3%) underwent a right heart catheterization  but did not 
receive an implant primarily because of anatomical/physiological conditions identified 
during the RHC. Of the 550 randomized patients, 270 were assigned to the Treatment 
group and 280 to the Control group.  The two groups were similar with respect to baseline 
characteristics (Table 5).   

Table 5. Patient Demographics 

 

Randomized Group 

 

Variables 

Treatment 

(N=270) 

Control 

(N=280) 

p-value

[1]

 

Age (years) 

 61.3 ± 12.98 (270)   61.8 ± 12.73 (280) 

0.5927 

Male 

194/270 (71.9%) 

205/280 (73.2%) 

0.7745 

Race (White) 

196/270 (72.6%) 

205/280 (73.2%) 

0.9236 

Systolic BP (mmHg) 

121.2 ± 22.52 (270)  123.2 ± 21.01 (280) 

0.1286 

Heart Rate (bpm) 

 72.4 ± 12.91 (269)   73.0 ± 12.14 (280) 

0.4873 

BMI 

 30.5 ± 6.50 (270) 

 30.9 ± 7.35 (280) 

0.6228 

BUN (mg/dL) 

 29.6 ± 17.99 (248)   28.1 ± 16.17 (267) 

0.6325 

Creatinine (mg/dL) 

  1.4 ± 0.47 (270) 

  1.4 ± 0.42 (280) 

0.5560 

GFR (mL/min/1.73m²) 

 60.4 ± 22.50 (270)   61.8 ± 23.20 (280) 

0.5638 

Ejection Fraction (EF>=40%) 

62/270 (23.0%) 

57/279 (20.4%) 

0.5343 

Cardiac Output (L/min) 

  4.5 ± 1.41 (270) 

  4.6 ± 1.54 (278) 

0.5499 

Cardiac Index (L/min/m²) 

  2.1 ± 0.59 (270) 

  2.2 ± 0.64 (278) 

0.4405 

PVR 

  2.9 ± 2.02 (270) 

  2.7 ± 1.82 (278) 

0.4609 

PA Wedge Pressure (mmHg)   17.5 ± 7.97 (270) 

 19.0 ± 8.12 (280) 

0.0276 

PA Mean Pressure (mmHg) 

 28.9 ± 9.92 (270)   29.9 ± 10.05 (280) 

0.3021 

CRT-D/ICD Implant 

179/270 (66.3%) 

197/280 (70.4%) 

0.3145 

Ischemic Cardiomyopathy 

158/270 (58.5%) 

174/280 (62.1%) 

0.4327 

Hypertension 

207/270 (76.7%) 

220/280 (78.6%) 

0.6100 

Hyperlipidemia 

204/270 (75.6%) 

218/280 (77.9%) 

0.5458 

Coronary Artery Disease 

182/270 (67.4%) 

202/280 (72.1%) 

0.2290 

History of MI 

134/270 (49.6%) 

137/280 (48.9%) 

0.9320 

Diabetes Mellitus 

130/270 (48.1%) 

139/280 (49.6%) 

0.7337 

AFIB 

120/270 (44.4%) 

135/280 (48.2%) 

0.3932 

COPD 

76/270 (28.1%) 

83/280 (29.6%) 

0.7078 

ACE/ARB use 

205/270 (75.9%) 

222/280 (79.3%) 

0.3584 

Beta Blocker use 

243/270 (90.0%) 

256/280 (91.4%) 

0.6595 

[1]

 Wilcoxon Rank-Sum Test for continuous measures and Fisher's exact test for categorical measures. 

 

 

14

 

Summary of Contents for CardioMEMS CM1000

Page 1: ...CardioMEMS HF System PA Sensor and Delivery System Model CM2000 User s Manual ...

Page 2: ...plied sterile for single use only After use dispose of the Delivery System Do not resterilize Caution Federal U S law restricts this device to sale by or on the order of a physician Unless otherwise noted indicates that the name is a trademark of or licensed to St Jude Medical or one of its subsidiaries ST JUDE MEDICAL and the nine squares symbol are trademarks and service marks of St Jude Medical...

Page 3: ...re 11 Patient Identification Card 12 Patient Counseling Information 12 Clinical Study Information 13 Introduction 13 Purpose 14 Methods 13 Patient Demographics and Disposition 14 Primary and Secondary Endpoint Results 15 Primary Safety Endpoints 15 Primary Efficacy Endpoint 16 Secondary Endpoints 16 Medical Management 17 Results from the Entire Randomized Access Period 17 HF Hospitalizations 17 Mo...

Page 4: ...ice clinic hospital or patient s home The data provided by the system includes PA pressure waveform Systolic Diastolic and Mean PA pressure Heart Rate This hemodynamic data is transmitted to a secure website that serves as the patient database so that PA monitoring information is available at all times through the internet Changes in PA pressure can be used in conjunction with heart failure signs ...

Page 5: ...ve to diuretic therapy or who are on chronic renal dialysis Patients with congenital heart disease or mechanical right heart valve s Patients with known coagulation disorders Patients with a hypersensitivity or allergy to aspirin and or clopidogrel Patients who have undergone implantation of a Cardiac Resynchronization Device CRT within the past 3 months If the patient s BMI is greater than 35 mea...

Page 6: ...e CardioMEMS HF System is affected by a change in body temperature 1mm Hg ΔºC Accuracy of the CardioMEMS HF System is slightly affected by large changes in elevation between the initial baseline calibration and subsequent measurements 2mm Hg 305 meters elevation change An accurate right heart catheterization is required to set system baseline mean pressure If a patient has a sensor implanted and a...

Page 7: ... The effects of therapeutic ultrasound have not been determined If therapeutic ultrasound is required avoid contact with the sensor MRI Information Non clinical testing demonstrated that the sensor is MR Conditional A patient with this device can be scanned safely immediately after implantation under the following conditions o Static magnetic field of 1 5 or 3 0 Tesla o Maximum spatial gradient ma...

Page 8: ...ion o Bronchitis o Pneumonia o Acute Bronchitis o Groin abscess o Methicilin resistant staphylococcal aureus infection o Pulmonary Infiltration o Sepsis Arrhythmias o Ventricular tachycardia o Atrial fibrillation o Ventricular arrhythmia o Ventricular fibrillation o Atrial fibrillation with rapid ventricular response o Atrial flutter o Cardiac dysrhythmias o Tachycardia o Wide complex tachycardia ...

Page 9: ...e baseline Fluoroscope with digital angiography capabilities and ability to record and recall images C arm or fixed Blood pressure monitoring equipment for a right heart catheterization procedure Saline solution Radiopaque contrast media Package Inspection Inspect the package carefully before opening and check the Use By date on the product label Implant of the sensor is not recommended after its ...

Page 10: ...gastrointestinal bleeding during the period in which dual antiplatelet therapy is given the physician should consider a proton pump inhibitor Patients at risk include the elderly or those with a history of gastroduodenal ulcers GERD esophagitis intestinal polyps or cancer Patients who smoke or who are using steroids or non steroidal anti inflammatory drugs may also be at risk Implantation Procedur...

Page 11: ... vessel is within the lower lobe of either lung and the vessel is directed towards the feet and back Vessel diameter is 7 mm and has 30 degree angulation where body of Sensor will be placed Vessel diameter is 5 8 mm where the distal loop of Sensor will be placed See figure 3 Figure 3 Target implant site 8 Insert the sensor delivery guidewire through the PA catheter across the target implant site 9...

Page 12: ...essure Baseline button on the Hospital Electronics System Enter the mean PA pressure value measured by the PA catheter 20 Set Cardiac Output Baseline Press the Set CO Baseline button on the Hospital Electronics System Enter the Cardiac Output value which was measured by the PA catheter Optional 21 Press the Take Reading button to capture baseline reading s 22 Remove antenna from under patient s ba...

Page 13: ...F hospitalizations by managing patient PA pressures using the CardioMEMS HF System Methods Study Design 550 patients with NYHA Class III HF and a prior HF hospitalization within 12 months were randomized to standard of care plus the CardioMEMS HF System Treatment group 270 patients or to standard of care only Control group 280 patients All patients were implanted with the PA Sensor and took daily ...

Page 14: ... similar with respect to baseline characteristics Table 5 Table 5 Patient Demographics Randomized Group Variables Treatment N 270 Control N 280 p value 1 Age years 61 3 12 98 270 61 8 12 73 280 0 5927 Male 194 270 71 9 205 280 73 2 0 7745 Race White 196 270 72 6 205 280 73 2 0 9236 Systolic BP mmHg 121 2 22 52 270 123 2 21 01 280 0 1286 Heart Rate bpm 72 4 12 91 269 73 0 12 14 280 0 4873 BMI 30 5 ...

Page 15: ...n 567 98 6 were free from DSRC at 6 months lower confidence limit 97 3 p 0 0001 This lower limit of 97 3 is greater than the pre specified OPC of 80 Table 6a and 6b There were no sensor explants or repeat implants and all sensors were operational at 6 months for a freedom from sensor failure of 100 lower confidence limit 99 3 p 0 0001 This lower limit of 99 3 is greater than the pre specified OPC ...

Page 16: ... 85 p 0 0002 Control Group n 280 120 0 44 1 p value and hazard ratio from negative binomial regression model Secondary Endpoints The four secondary efficacy endpoints were analyzed hierarchically at 6 months Table 9 At baseline both Treatment and Control patients had similar PA mean pressures When compared with patients in the Control group the patients in the Treatment group had greater reduction...

Page 17: ...ndomized Access period was slightly larger than that seen during the 6 month primary endpoint period 33 vs 28 indicating durability of the treatment effect The number needed to treat NNT per year to prevent one HF hospitalization was 4 For every 100 patients treated 23 HF hospitalizations would be prevented per year Table 10 HF Hospitalization Rates During Randomized Access Number of HF Hospitaliz...

Page 18: ... which cannot be separated from the treatment effect Treatment Effects in Women The CHAMPION study was not powered to show statistical significance for gender thus a complete determination of the effect of the device in women cannot be made At the request of FDA a post hoc gender analysis was conducted for the CHAMPION study and the initial finding of a treatment by gender interaction for the effe...

Page 19: ...creating a competing risk for HF hospitalizations i e fewer control women were alive to have HF hospitalizations Figure 6 examines Freedom from HF Hospitalization or Death and indicates a non significant trend favoring women in the treatment group Figure 4 Freedom from HF Hospitalization over the Full Randomized Period Part 1 Figure 5 Freedom from Death over the Full Randomized Period Part 1 Figur...

Page 20: ...on Endpoint of HFR hospitalization 0 573 0 191 0 0027 Part 1 Part 2 Cox Model Endpoint of first HFR hospitalization or Death 0 204 0 249 0 4121 Cox Model Endpoint of first HFR hospitalization 0 427 0 284 0 1331 AG Model with Frailty Endpoint of HFR hospitalization or Death 0 376 0 274 0 1697 AG Model with Frailty Endpoint of HFR hospitalization 0 588 0 271 0 0301 AG Model with RSE Endpoint of HFR ...

Page 21: ...ders 2 0 7 2 33 3 1 0 4 1 9 1 3 0 5 3 17 6 0 0 0 0 Hemoptysis 1 1 1 1 2 2 0 0 Dyspnea 1 1 0 0 1 1 0 0 Cardiac disorders 1 0 4 1 16 7 1 0 4 1 9 1 2 0 4 2 11 8 0 0 0 0 Congestive heart failure 1 1 0 0 1 1 0 0 Ventricular tachycardia 0 0 1 1 1 1 0 0 Nervous system disorders 0 0 0 0 0 0 1 0 4 1 9 1 1 0 2 1 5 9 0 0 0 0 Dizziness 0 0 1 1 1 1 0 0 Vascular disorders 0 0 0 0 0 0 1 0 4 1 9 1 1 0 2 1 5 9 0 0...

Page 22: ...s Over Part 1 and Part 2 Table 15 Serious Adverse Events Over Part 1 and Part 2 Part 1 Part 2 Treatment 270 Control 280 All Patients 550 All Patients 347 Subjects Events Subjects Events Subjects Events Subjects Events All Patients with an Event 198 73 3 797 217 77 5 956 415 75 5 1753 201 57 9 647 Cardiac disorders 138 51 1 333 151 53 9 443 289 52 5 776 119 34 3 238 Congestive heart failure 99 204 ...

Page 23: ...tricular tachycardia 0 0 1 1 1 1 0 0 Sustained ventricular tachycardia 1 1 0 0 1 1 0 0 Tachycardia 0 0 1 1 1 1 0 0 Tricuspid insufficiency 0 0 1 1 1 1 0 0 Ventricular ectopic beats 1 1 0 0 1 1 0 0 Ventricular rhythm 0 0 1 1 1 1 0 0 Wide complex tachycardia 0 0 1 1 1 1 0 0 Wide complex ventricular tachycardia 1 1 0 0 1 1 0 0 Asystole 0 0 0 0 0 0 2 2 Congestive cardiomyopathy 0 0 0 0 0 0 1 1 End sta...

Page 24: ...1 1 0 0 Serratia infection 0 0 1 1 1 1 0 0 Sinusitis 0 0 1 1 1 1 1 1 Staphylococcal infection 1 1 0 0 1 1 0 0 Urosepsis 1 1 0 0 1 1 0 0 Viral infection 1 1 0 0 1 1 1 1 Viremia 0 0 1 1 1 1 0 0 Wound infection 0 0 1 1 1 1 0 0 Arthritis infective 0 0 0 0 0 0 1 1 Bronchopneumonia 0 0 0 0 0 0 1 1 Clostridium difficile colitis 0 0 0 0 0 0 3 3 Cytomegalovirus viremia 0 0 0 0 0 0 1 1 Febrile cold excl flu...

Page 25: ...atigue extreme 1 1 0 0 1 1 0 0 Febrile reaction 0 0 1 1 1 1 0 0 Fever of unknown origin 0 0 1 1 1 1 1 1 Infusion site bleeding 0 0 1 1 1 1 0 0 Multi organ failure 0 0 1 1 1 1 0 0 Non cardiac chest pain 0 0 1 1 1 1 1 1 Substernal chest pain 0 0 1 1 1 1 0 0 Sudden death 1 1 0 0 1 1 0 0 Swelling 1 1 0 0 1 1 0 0 Edema 0 0 0 0 0 0 1 1 Malaise 0 0 0 0 0 0 1 1 Organ failure 0 0 0 0 0 0 1 1 Thrombus in ca...

Page 26: ...1 1 2 2 Unresponsive to stimuli 0 0 1 1 1 1 1 1 Vasovagal symptoms 0 0 1 1 1 1 0 0 Weakness left or right side 0 0 1 1 1 1 0 0 Brain injury 0 0 0 0 0 0 1 1 Restless leg syndrome 0 0 0 0 0 0 1 1 Todd s paralysis 0 0 0 0 0 0 1 1 Transient ischemic attacks 0 0 0 0 0 0 2 2 Vocal cord paralysis 0 0 0 0 0 0 1 1 Renal and urinary disorders 33 12 2 41 24 8 6 34 57 10 4 75 20 5 8 22 Acute on chronic renal ...

Page 27: ...ischemia 0 0 0 0 0 0 1 1 Reflux esophagitis 0 0 0 0 0 0 1 1 Right upper quadrant pain 0 0 0 0 0 0 1 1 Small bowel obstruction 0 0 0 0 0 0 1 1 Metabolism and nutrition disorders 26 9 6 33 28 10 0 38 54 9 8 71 24 6 9 30 Dehydration 7 9 5 5 12 14 8 8 Hyperglycemia 3 4 5 6 8 10 1 1 Hypoglycemia 4 4 2 2 6 6 2 2 Failure to thrive 2 2 3 4 5 6 1 1 Hypokalemia 2 2 3 3 5 5 3 3 Hypovolemia 2 2 3 3 5 5 0 0 El...

Page 28: ...ular assist device insertion 0 0 0 0 0 0 1 1 Injury poisoning and procedural complications 18 6 7 21 16 5 7 19 34 6 2 40 15 4 3 16 Lead dislodgement 2 2 2 2 4 4 0 0 Hip fracture 0 0 3 3 3 3 1 1 Bleeding postoperative 1 1 1 1 2 2 0 0 Device malfunction 0 0 2 2 2 2 0 0 Fall 2 2 0 0 2 2 2 2 Head injury 0 0 2 2 2 2 0 0 Lead conductor fracture 2 2 0 0 2 2 0 0 Subdural hematoma 2 2 0 0 2 2 2 2 Accidenta...

Page 29: ...4 0 20 Anemia 11 12 8 10 19 22 11 12 Thrombocytopenia 1 1 1 1 2 2 1 1 Anemia microcytic 1 1 0 0 1 1 0 0 Leukocytosis 0 0 1 1 1 1 0 0 Neutropenia 0 0 1 1 1 1 0 0 Anemia aggravated 0 0 0 0 0 0 1 1 Hemolysis 0 0 0 0 0 0 1 5 Neutropenic fever 0 0 0 0 0 0 1 1 Investigations 10 3 7 10 5 1 8 6 15 2 7 16 3 0 9 4 Serum creatinine increased 2 2 1 2 3 4 0 0 Transplant evaluation 2 2 0 0 2 2 0 0 Anticoagulati...

Page 30: ...yroidism 1 1 0 0 1 1 1 1 Myxedema 0 0 1 1 1 1 0 0 Immune system disorders 2 0 7 2 1 0 4 1 3 0 5 3 0 0 0 0 Amyloidosis 1 1 0 0 1 1 0 0 Heart transplant rejection 0 0 1 1 1 1 0 0 Transplant rejection 1 1 0 0 1 1 0 0 Skin and subcutaneous tissue disorders 0 0 0 0 3 1 1 3 3 0 5 3 3 0 9 4 Diabetic ulcer 0 0 1 1 1 1 0 0 Foot ulcer 0 0 1 1 1 1 0 0 Venous stasis ulcer 0 0 1 1 1 1 0 0 Decubitus ulcer 0 0 0...

Page 31: ...nd an in situ thrombosis during the right heart catheterization procedure Both patients were treated and recovered without sequela There were no additional SADEs over Part 2 of the clinical trial FCC Statement This device is approved for wireless transmission under FCC ID number R3PCS A 000051 This device complies with Part 15 of the FCC Rules Operation is subject to the following conditions This ...

Page 32: ...Manufacturer St Jude Medical 387 Technology Circle NW Atlanta Georgia 30313 USA 866 240 3335 sjm com July 2015 LA 400275 G ...

Reviews:

No comments

Brands by name

Popular brands

Load more brands